In the past few years, artificial intelligence (AI) has risen from lab prototypes to a major force behind new ideas in healthcare. A new wave of entrepreneurs is altering how patients are treated by using AI to guide imaging in real time and automating boring clinical paperwork. According to Fierce Healthcare, AI-enabled digital health firms got 62% of all digital health funding in the first half of 2025, which was approximately $4 billion—83% more than non-AI peers. Venture investors are putting a lot of money on the line: Abridge, the best company for AI writing, raised $300 million in a Series E financing in June, just four months after raising $250 million in a Series D round.
Fierce Health Care.
Below, we showcase five disruptive AI businesses that are transforming the way healthcare is delivered by deploying cutting-edge technologies, passing major regulatory milestones, and having a quantifiable effect on patients.
PathAI: Changing Pathology with FDA-Cleared AI
Headquarters: Boston, MA
It began in 2016 with Andy Beck, MD, PhD.
Pathology is the most important part of generating accurate diagnoses, yet needing to look at slides by hand and variances across observers slows down standard procedures. PathAI’s AISight® Dx digital pathology platform solves these problems right away. According to GlobeNewswire, it gained FDA 510(k) approval for use in clinical settings for primary diagnosis on June 30, 2025. With this approval, PathAI may make substantial changes to its software and hardware without having to submit them over and over again. This is the first time this has happened in digital pathology.
In July 2025, PathAI debuted its Precision Pathology Network (PPN). It is a collection of the best anatomic pathology labs that use AISight® to speed up collaborations in biopharma, the creation of real-world data, and precise diagnosis. In April 2025, four additional labs joined PathAI’s AI-driven workflows, which now cover more diagnostic uses. These new labs will aid with classifying cancer cells based on their wi-fi signals and finding new biomarkers.<sp
PathAI has gotten $255 million in five rounds of investment. Adage Capital, General Atlantic, and D1 Capital Partners Tracxn are the key investors. These tools help with current research and development in explainable AI, deep-learning algorithms, and links with big laboratory information systems.
New Ideas and Effects That Matter
- Digital Slide Management: AISight® is a cloud-based system that lets you handle cases and photos all in one location, which can speed up the process by up to 40%.
- Explainable AI: Pathologists can grasp how algorithms make judgments better using interactive visual overlays, which makes them more likely to utilize them.
- Biopharma Partnerships: The Precision Pathology Network speeds up the process of acquiring data for targeted medicines, decreasing trial delays by up to 30%.
Tempus AI: Using AI and data to improve precision medicine
The main office is in Chicago, Illinois.
Eric Lefkofsky founded the business in 2015.
Tempus is now a leader in AI-driven precision medicine because it uses large datasets from molecular, clinical, and radiomic sources to tailor treatments for cancer, heart disease, and other illnesses. On July 16, 2025, the FDA accorded Tempus ECG-Low EF, an AI module that automatically discovers patients with low ejection fraction from routine ECGs, 510(k) clearance. This helps doctors step in early if someone is at risk of cardiac failure.
Tempus Next, the Care Pathway Intelligence Platform, introduced breast cancer in June 2025. This filled in critical gaps in care based on guidelines and tested tens of thousands of patients in its network of providers. This extension is based on how well the platform worked for lung cancer. It increased compliance with screening methods by 25% in just six months of use.
The NASDAQ listed Tempus under the ticker TEM in June 2024. It had a market valuation of more than $4 billion. Some of its backers are Google Ventures, Franklin Templeton, and the SoftBank Vision Fund. This shows that they think Tempus can use genomic sequencing, machine learning, and a lot of clinical metadata to give relevant information.
Changes and Effects That Matter
- Tempus One’s Generative AI Clinical Assistant works with electronic health records (EHRs) to help doctors by answering their queries, summarizing patient histories, and making suggestions for orders based on recommendations. This saves 30% of the time it takes to study charts.
- The xM test looks at circulating tumor DNA to see how effectively immunotherapy works. Compared to tissue-based approaches, it is 90% accurate.
- Tempus works in 34 countries and helps with research and care at big academic centers and community hospitals.
Viz.ai: AI-Powered Acute Care and Clinical Coordination
The main office of the corporation is in San Francisco, California.
Chris Mansi, MD, founded the business in 2016.
Viz.ai was the first startup to apply real-time AI to discover major problems including large vessel occlusion (LVO) strokes and cerebral hemorrhages in CT scans. This lets the care workers know immediately away so they can move more quickly. In July 2025, Black Book Research ranked Viz.ai the best AI-powered acute care vendor after talking to 1,364 doctors. They looked at 11 important performance characteristics, like how well it identified patients and how well it coordinated with other systems.
Earlier in April 2025, Viz.ai won its third Edison Award™ for machine-learning breakthrough in a row. This time, it was for its Viz HCM module, which can find hypertrophic cardiomyopathy in heart scans with 95% accuracy. In May 2025, it was revealed that the Viz COPD module would be used to find and help high-risk chronic obstructive pulmonary disease patients early by analyzing EHR data. This was part of a long-term relationship between Sanofi and Regeneron.
More than 1,700 hospitals around the world have employed Viz.ai’s products. They have been demonstrated to shorten the time it takes to seek treatment for a stroke by an average of 32% and enhance outcomes down the road, such as a 20% decline in impairment ratings after 90 days.
New Ideas That Are Important and What They Mean
- Alerts Powered by AI: Automated triage alerts can shorten the time it takes to turn on stroke codes by as much as 15 minutes.
- Multimodal Expansion: The Viz Oncology™ Suite, which came out in May 2025, speeds up cancer treatment processes from neuroimaging to cardiology and oncology.
- Explainability and Trust: Clinicians can double-check AI results before making a choice because of visual overlays and confidence measures.
Abridge: Ambient AI Scribes to Help Clinicians Not Get Burned Out
The main office is in Pittsburgh, Pennsylvania.
Dr. Shiv Rao launched it in 2018.
Clinical documentation is a big reason why doctors get burned out. They have to do up to two hours of paperwork for every hour of patient treatment. Abridge features an AI scribe that listens to discussions between doctors and patients and writes down what they say in real time. This makes structured clinical notes that go straight into the EHR. Abridge raised $300 million in a Series E investment led by Andreessen Horowitz in June 2025. In just four months, this made it worth $5.3 billion.
Abridge has worked with more than 150 enterprise health systems in the U.S. so far, handling more than 1.5 million clinical contacts and saving an average of 40 minutes of documentation time for each patient visit. It can recognize phrases with 95% accuracy and provide templates for certain specialties using its own AI models that were trained on a sample of more than 2 million medical chats that had been de-identified.
Changes and Effects That Matter
- On platforms like Epic and Cerner, notes fill in automatically, which makes it easier to connect EHRs.
- Adaptive Learning: The system grows better as clinicians give feedback and the system adjusts.
- Reimbursement Optimization: By making sure that bills are right using embedded code inspection, you can increase your income by up to 8%.
Butterfly Network: Using AI to Make Ultrasound More Accessible to Everyone
The primary headquarters is in Burlington, Massachusetts.
It was started by Jonathan Rothberg in 2011.
The Butterfly iQ3™ from Butterfly Network is a portable probe that uses semiconductors and works with a smartphone to take photos of the full body. The company made $21.2 million in the first quarter of 2025. This was 20% more than what it made in the same quarter previous year. This was because the U.S. health system quickly adopted its AI guidance features and rolled them out.
The iQ3 won the 2024 Prix Galien USA Award for Best Medical Technology. Its AI-powered picture interpretation and guided workflow make sure that the image quality is always good, even for beginners, by showing the proper probe positioning in real time. Researchers at Rutgers Robert Wood Johnson Medical School reported in January 2025 that point-of-care ultrasound decreased the cost of inpatient care by half and made diagnoses 35% more accurate.
Important New Ideas and Their Effects
- AI Guidance: Integrated algorithms help with imaging the fetus, heart, and lungs, which cuts down on scan errors by 30%.
- Scalable Platform: Cloud storage and analytics make tele-ultrasound and remote consulting possible.
- Global Reach: More than 1,200 hospitals in 50 nations utilize it, which makes it easier for everyone to get tests.
Moving on from challenges and creating trust
AI entrepreneurs are altering healthcare swiftly, but they need to fix four fundamental issues:
- Following the rules: Getting FDA approvals, CE marks, and following data protection laws requires a lot of effort and money.
- Data Privacy and Security: Strong encryption and governance structures are essential to keep patient data safe and make sure HIPAA and GDPR laws are fulfilled.
- Integration Complexity: To save clinicians from getting frustrated and slowing down adoption, EHRs and existing workflows must function together without any problems.
- Explainability and Bias: Doctors need to be able to grasp what AI outputs mean, and algorithms need to be trained on a lot of different datasets to avoid disparities.
These startups perform peer-reviewed research, acquire permission from regulators, and work with prominent institutions to test their ideas in real life, all in line with the principles of Experience, Expertise, Authoritativeness, and Trustworthiness (EEAT).
Questions that people often ask
- What made you pick these startups?
We put firms with FDA or comparable approvals, a lot of venture financing, peer-reviewed proof that their products work in real life, and deployments with more than one health system partner at the top of our list. - What kinds of technology do they all utilize to develop their solutions?
Some of the most significant elements that make this feasible include deep learning, computer vision, natural language processing, generative AI, and edge computing enabling on-device inference. - How do these AI tools help doctors execute their jobs?
Most solutions come with EHR plugins, DICOM connections, or RESTful APIs already built in. This means that they won’t be too hard to use and doctors will be able to get started right away. - Are these technologies available to individuals all over the world?
Yes, a lot of businesses originated in the U.S., but they have since extended to Europe, Asia, and beyond. They usually do this by creating clever alliances and respecting local norms. - What will AI do in the future in healthcare?
Federated learning for training models that keeps privacy safe, multimodal AI that brings together imaging, genomics, and EHR data, and autonomous processes that make practitioners even more productive are all part of the next frontier.
Finally, AI startups are launching a new age in healthcare that focuses on accuracy, speed, and simplicity of access. These five companies highlight how new technologies can make things better, cheaper, and easier for doctors. They do things like pathology, point-of-care imaging, and ambient documentation. As laws and standards for interoperability become more established, we can expect the AI ecosystem to grow even more, which will be good for both providers and patients.
References
- Fierce Healthcare: “Big bets on healthcare AI push digital health funding to $6.4B” (Jun 2025) – Fierce Healthcare
- Stat News: “Abridge raises $300M as the market for AI scribes heats up” (Jun 24, 2025) – STAT
- PathAI Press Release: “PathAI Receives FDA Clearance for AISight Dx Platform” (Jun 30, 2025) – GlobeNewswire
- PathAI Press Release: “PathAI Launches Precision Pathology Network” (Jul 8, 2025) – National Law Review
- Trac xn: “PathAI – Funding & Investors” (Jul 2025) – Tracxn
- Tempus Press Release: “Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG‑Low EF Software” (Jul 16, 2025) – https://www.tempus.com/news/pr/tempus-receives-u-s-fda-510k-clearance-for-tempus-ecg-low-ef-software Tempus
- Tempus Press Release: “Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer” (Jul 8, 2025) – Tempus
